Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168629
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
DC FieldValueLanguage
dc.contributor.authorDíaz-Rodríguez, Elena-
dc.contributor.authorPandiella, Atanasio-
dc.date.accessioned2018-08-13T10:21:02Z-
dc.date.available2018-08-13T10:21:02Z-
dc.date.issued2016-
dc.identifierdoi: 10.3109/10428194.2015.1037752-
dc.identifiere-issn: 1029-2403-
dc.identifierissn: 1042-8194-
dc.identifier.citationLeukemia and Lymphoma 57(1): 168-176 (2016)-
dc.identifier.urihttp://hdl.handle.net/10261/168629-
dc.description.abstractThe use of thalidomide derivatives (IMIDs) has improved multiple myeloma prognosis, through an unknown mechanism of action. Recently one molecular target, the cereblon (CRBN) protein, has been identified. CRBN acts by binding to DDB1-CUL4-ROC1 forming a ubiquitin ligase multiprotein complex. We have generated antibodies to different regions of CRBN protein, and analyzed the biological consequences of augmenting or decreasing CRBN levels. CRBN was expressed in all the myeloma cell lines tested, independently of their sensitivity to IMIDs, and the CRBN-DDB1-CUL4 complex was efficiently formed. At the molecular level, long-term treatment with IMIDs induced a slight decrease in CRBN levels and a reduction in the CRBN-DDB1-CUL4 complex. Interestingly, treatment with other anti-myeloma drugs downregulated cellular contents of CRBN, and in a much faster fashion. These results suggest that CRBN is an important mediator of the cellular response to IMIDs, but also critical in the maintenance of cell viability and/or proliferation.-
dc.publisherTaylor & Francis-
dc.rightsclosedAccess-
dc.subjectIMIDs-
dc.subjectMyeloma-
dc.subjectThalidomide-
dc.subjectCancer-
dc.subjectCRBN-
dc.titleModulation of cereblon levels by anti-myeloma agents-
dc.typeartículo-
dc.identifier.doi10.3109/10428194.2015.1037752-
dc.date.updated2018-08-13T10:21:02Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.relation.csic-
dc.identifier.pmid25860244-
item.fulltextNo Fulltext-
item.openairetypeartículo-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record

PubMed Central
Citations

4
checked on Nov 23, 2021

SCOPUSTM   
Citations

5
checked on Nov 30, 2021

WEB OF SCIENCETM
Citations

6
checked on Dec 1, 2021

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.